A Dark Vector Cognition product

Item 4. Controls and Procedures

2K characters. Original on sec.gov ·

Item 4. Controls and Procedures

We performed an evaluation of the effectiveness of our disclosure controls and procedures as of September 30, 2023. The evaluation was performed with the participation of senior management of each business segment and key Corporate functions, under the supervision of our Chairman, President and Chief Executive Officer (CEO) and our Executive Vice President and Chief Financial Officer (CFO). Based on this evaluation, the CEO and CFO concluded that our disclosure controls and procedures were operating and effective as of September 30, 2023.

There were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2023 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following provides information about our third quarter of 2023 repurchases of equity securities that are registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended:

Period (shares in thousands)**Total Number of Shares Purchased ***Average Price Paid per Share (excluding commissions)**Total Number of Shares Purchased as part of Publicly Announced Plan ***Maximum Number of Shares that may yet be Purchased under the Plan
July 2, 2023 – August 5, 2023455$72.1745534,775
August 6, 2023 – September 2, 20231,53076.731,53033,245
September 3, 2023 – September 30, 20231,10076.691,10032,145
Total3,085$76.043,085

** On July 24, 2023, our Board of Directors approved a new program for the repurchase of up to 35 million shares of our common stock. This share repurchase program has no expiration date and replaced the prior 2022 share repurchase program. There were 230 thousand shares repurchased under the 2022 program during the period July 2, 2023 through July 23, 2023.*

Previous: Item 3. Quantitative and Qualitative Disclosures About Market Risk · Next: Item 6. Exhibits